(Q46750958)

24 December 2017

title

Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme (English)

1 reference

24 December 2017

cardiac magnetic resonance imaging

main subject

1 reference

C Anderson

1

1 reference

24 December 2017

publication date

1 January 2005

1 reference

24 December 2017

Journal of International Medical Research

published in

1 reference

24 December 2017

volume

33 Suppl 1

1 reference

24 December 2017

page(s)

50A-57A

1 reference

24 December 2017

Assessment of left ventricular mass by cardiovascular magnetic resonance.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Left Ventricular Mass and Risk of Stroke in an Elderly Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Blood pressure-independent effects in rats with human renin and angiotensinogen genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Blood-pressure reduction and cardiovascular risk in HOPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

The past, present and future of hypertension management: a potential role for AT(1)-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Telmisartan: a review of its use in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Pre-clinical and clinical experience of telmisartan in cardiac remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Usefulness of B-type natriuretic peptide (BNP) as a screen for left ventricular abnormalities in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Biochemical detection of left-ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Left ventricular mass and volume: fast calculation with guide-point modeling on MR images.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Performance characteristics of four automated natriuretic peptide assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study e

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S107

10.1177/14732300050330S107

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017